Eyenovia To Feature Its Suite Of Commercial Products And The Optejet® Dispenser At Upcoming National Eyecare Meetings
News
Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston
Will also…
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NewsEMERYVILLE, Calif. and NEW YORK (March 13, 2024) – NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to…
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
NewsCompany to host an investor conference call and webcast at 4:30pm EDT
NEW YORK—March 11, 2024—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release…
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
NewsApproval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery
Eyenovia plans to launch in the U.S. as soon as this…
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
NewsRedwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi
NEW YORK— February 13, 2024—Eyenovia, Inc. (NASDAQ:…
Eyenovia Re-Acquires Development And Commercialization Rights To Micropine In The U.S. And Canada
NewsMicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007
Part of corporate strategy to expedite commercialization of advanced…
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
NewsAcquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals
Announced FDA approval of Coastline International as contract manufacturer for Mydcombi…
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NewsAnticipates having product available to ship in January 2024
NEW YORK— November 2, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of…
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
NewsCourse to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis
NEW YORK— October 30, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company…
Eyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®
NewsIn rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions.
Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual…